<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221129056657N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-11-14</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the preventive effect of ethanol and gentamicin in central venous catheter infection</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the preventive effect of gentamicin-lock and ethanol-lock in central venous catheter infection in children admitted to the pediatric intensive care unit.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>228</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73284</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Individual simple randomization
Random number table randomization tool using www.randomization.com
Allocation Concealment method: envelopes closed. In this method, first, a random sequence is created, then based on the size of the research sample, a number of envelopes with aluminum wrappers (in order to avoid the clarity of the contents of the envelopes), are prepared and each of the generated random sequences is recorded on a card, and the cards are inside The letter envelopes are placed in order. In order to maintain a random sequence, the outer surface of the envelopes is numbered in the same order. Finally, the lid of the letter envelopes is glued and placed in a box. At the time of starting the registration of participants, based on the order in which eligible participants entered the study, one of the envelopes will be opened and the assigned group of that participant will be revealed, Blinding description: For blinding,  statistical consultants and data analysts were unaware of the patient's randomization and placement in the therapy group.</study_design>
      <phase>2</phase>
      <hc_freetext>Infection and inflammatory reaction due to other cardiac and vascular devices, implants and grafts.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Gentamicin with a volume of 0.25 cc (10 mg) is mixed with 9.75 cc of normal saline (ideally 1 mg in 1 cc) with a total volume of 10 cc. We inject the contents of the syringe of 5 cc of normal saline into the lumen and then aspirate. After the blood returns, the amount aspirated in the syringe is equivalent to the volume required to seal the lumen. Then that lumen is not used for 4 hours. Then the above volume is thrown away and varnish therapy is immediately performed in the other lumen. Two-lumen and three-lumen catheters will be used depending on the age and condition of the patient, and each lumen will be subjected to lock therapy separately and respectively. Lock therapy is performed once a day in each line and continues for 7 days. Intervention 2: Intervention group: 70% alcohol is used. The volume of 0.2 cc is used to fill the lumen and remains in each lumen of the catheter for 4 hours, and during this time, the lumen must be unused. Two-lumen and three-lumen catheters are used depending on the age and condition of the patient. and each lumen will be subjected to lock therapy separately and in order. Before and after each lock therapy with ethanol, the line is washed with 5 to 10 cc of normal saline. Lock therapy is performed once a day in each line and continues for 7 days. From the time of catheter insertion, lock therapy starts and continues as prophylaxis, and the final result is evaluated after 7 days. Intervention 3: Control group: As a control group, no drug is used to impregnate the catheter path.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data related to the main outcomes

When:
Six months after the results are published

To whom:
Academic institutions

Conditions:
For the purpose of research for the academic community

Where to obtain:
Dr. Gholamreza Khademi
khademigh@mums.ac.ir

How to obtain:
The request will be sent via email to Dr. Gholamreza Khademi and correspondence will be sent about two weeks after the registration of the data request.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Gholamreza Khademi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Akbar Children's Hospital-Shahid Kaveh Boulevard - Mashhad</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>٩١٧٧٨٩٧١۵٧</zip>
        <telephone>+98 51 3189 1780</telephone>
        <email>khademigh@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Gholamreza Khademi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Akbar Hospital, Shahid Kaveh Boulevard, Mashhad</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177897157</zip>
        <telephone>+98 51 3871 3801</telephone>
        <email>khademigh@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children between the ages of 1 month and 18 years admitted to the pediatric intensive care unit
Children undergoing central venous catheter implantation</inclusion_criteria>
      <agemin>1 month</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Hypersensitivity reaction to antibiotics or ethanol that is injected into the line.
Any dysfunction of the line occurs after drug injection</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T82.7</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Infection and inflammatory reaction due to other cardiac and vascular devices, implants and grafts</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Gentamicin with a volume of 0.25 cc (10 mg) is mixed with 9.75 cc of normal saline (ideally 1 mg in 1 cc) with a total volume of 10 cc. We inject the contents of the syringe of 5 cc of normal saline into the lumen and then aspirate. After the blood returns, the amount aspirated in the syringe is equivalent to the volume required to seal the lumen. Then that lumen is not used for 4 hours. Then the above volume is thrown away and varnish therapy is immediately performed in the other lumen. Two-lumen and three-lumen catheters will be used depending on the age and condition of the patient, and each lumen will be subjected to lock therapy separately and respectively. Lock therapy is performed once a day in each line and continues for 7 days.</i_keyword>
      <i_keyword>Intervention group: 70% alcohol is used. The volume of 0.2 cc is used to fill the lumen and remains in each lumen of the catheter for 4 hours, and during this time, the lumen must be unused. Two-lumen and three-lumen catheters are used depending on the age and condition of the patient. and each lumen will be subjected to lock therapy separately and in order. Before and after each lock therapy with ethanol, the line is washed with 5 to 10 cc of normal saline. Lock therapy is performed once a day in each line and continues for 7 days. From the time of catheter insertion, lock therapy starts and continues as prophylaxis, and the final result is evaluated after 7 days.</i_keyword>
      <i_keyword>Control group: As a control group, no drug is used to impregnate the catheter path.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Prevention of infection (blood culture). Timepoint: Seven days after the start of the intervention. Method of measurement: Bactec automatic blood culture machine.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Duration of stay in PICU. Timepoint: The time of discharge of the patient from the intensive care unit. Method of measurement: Use of checklists and patient records.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-09-23</approval_date>
        <contact_name>Committee on Ethics in Research, Faculty of Medicine, Mashhad University of Medical Sciences</contact_name>
        <contact_address>Qurashi Building، Daneshgah Street,Mashhad. Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
